Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- BIKEN Exits New Flu Vaccine Development Project, MHLW to Invite Other Makers
November 26, 2012
- LDP Policy Statement Calls for Perpetuation of New Drug Premium, Promotion of Switch-OTC Drugs
November 26, 2012
- MHLW Approves Additional Indications for 3 APIs/5 Products, Including Botox
November 26, 2012
- Even Non-Welfare Beneficiaries Have No Obligation to Use of Generics: Health Minister Mitsui
November 22, 2012
- MHLW Set to Clarify Review Procedures for Companion Diagnostics
November 21, 2012
- Translational Research, Biobank Projects Require Drastic Revision: Project Screening
November 21, 2012
- PAFSC’s 2nd Committee to Review 7th Biopharmaceutical RA Drug on Nov. 29
November 20, 2012
- PAFSC’s 1st Committee to Review 7 Products Including BMKK’s Apixaban on Nov. 30
November 20, 2012
- Re-Pricing of Generic Drugs Added to GRU’s Recommendation: Project Screening
November 20, 2012
- GRU to Propose that Welfare Beneficiaries Be Required to Use Generics as a Rule
November 20, 2012
- Temporary Halts in Generic Product Marketing, JGA Accelerates Efforts in Collecting Information
November 19, 2012
- Average Foreign Price Adjustment Results in NHI Price Lower than Manufacturing Cost for Pfizer Japan’s Tygacil: CSIMC
November 16, 2012
- CSIMC Subcommittee Eyes Price Cuts for Long-Listed Drugs with Slow Generic Penetration
November 16, 2012
- CSIMC OKs Listing for 15 APIs/22 Products; Peak Sales Estimated at 32.6 Billion Yen for Lotriga
November 15, 2012
- MHLW Director Suggests Being Ready for Increased Official Management if 3rd Round of Distribution Reform Fails
November 14, 2012
- Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
- Hodanren Asks MHLW to Disclose Discussions by Members of Drug Pricing Organization
November 13, 2012
- Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
- Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
- 15 Pharmacies Wrongly Claimed 41.6 Million Yen in Dispensing Fees Over 6 Year Period: Board of Audit
November 7, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…